Table 1 Characteristics of included studies in the meta-analysis
Study | Country | No. of patients (Exp/Con) | Age (years) | Eradication regimen | S.boulardii regimen | Diagnositic methods of H. pylori | |
|---|---|---|---|---|---|---|---|
Initial | Rechecking | ||||||
Hurduc 2009 | Romania | 90 (48/42) | 3~18 | Omeprozole / esomeprazole + clarothromycin + amoxicillin, 7–10 days | 250 mg bid, 28 days | RUT, histology | RUT, histology |
Zhang 2012 | China | 82 (41/41) | 11.13 ± 2.69/10.04 ± 2.10 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg qd, 7 days | Histology, RUT, UBT | UBT |
Zhang 2013 | China | 60 (30/30) | 9.82 ± 3.27/10.15 ± 3.34 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | UBT | UBT |
Zhao 2014 | China | 240 (120/120) | 7 ± 2/9 ± 2 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | RUT + UBT | UBT |
Zhou 2015 | China | 116 (58/58) | 8.91 ± 3.24/ 9.02 ± 3.16 | Omeprazole + amoxicillin + clarithromycin, 10 days | 125 mg bid, 10 days | RUT + UBT | UBT |
Bin 2015 | China | 205 (105/100)a | 13.33 ± 1.26 | Omeprazole + clarithromycin + amoxicillin / metronidazole, 14 days | 500 mg/day, 14 days | Histology, serology | UBT |
Chen 2015 | China | 240 (120/120) | 8.9 ± 1.9/9.6 ± 2.1 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | RUT + UBT | RUT + UBT |
Wang 2017 | China | 107 (57/50) | 9 ± 5 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg qd, 14 days | UBT | UBT |
Xiang 2017 | China | 500 (250/250) | 7.25 ± 2.16 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | UBT + RUT | UBT |
Dong 2018 | China | 160 (80/80) | 5~14 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | UBT + histology | UBT |
He 2019 | China | 120 (60/60) | 7.8 ± 2.1/ 9.2 ± 2.4 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | SAT or UBT | UBT |
Zhu 2019 | China | 80 (40/40) | 3~10 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | SAT or UBT | SAT or UBT |
Xiao 2021 | China | 90 (45/45) | 9.77 ± 2.32/10.23 ± 2.51 | Omeprazole + amoxicillin and clavulanate potassium + clarithromycin, 14 days | 250 mg bid, 14 days | RUT | UBT |
Zhang 2021 | China | 150 (100/50) | 3~14 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | Histology, or culture or RUT | UBT |
Liu 2023 | China | 79 (40/39) | 10.18 ± 2.12/10.36 ± 1.98 | Omeprazole + amoxicillin + clarithromycin, 14 days | 250 mg bid, 14 days | Histology, culture + RUT | UBT |